BUY Aurobindo Pharma — Sharekhan Research
bySharekhan ResearchHorizon: NA (inferred 1 year)11 Nov 2024via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
6 other SEBI-registered advisors have active long-term BUY calls on this stock, with 4 issued in the last 14 days
Advisor consensus · same horizon·10 Nov · yesterday
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Aurobindo Pharma
- SELL — Sahaj Agrawal, Kotak Securities21 Oct 2026 · ~2 weeks · target ₹1,540 · Active
- BUY — Arun Kumar Mantri12 Oct 2026 · ~2 weeks · target ₹1,745 · SL hit
- BUY — Ajit Mishra, Religare12 Oct 2026 · ~2 weeks · target ₹1,820 · SL hit
- BUY — Manas Jaiswal12 Oct 2026 · ~2 weeks · target ₹1,750 · SL hit
- BUY — Rupak De, LKP Securities9 Oct 2026 · ~2 weeks · target ₹1,800 · SL hit
More from Sharekhan Research
- BUY Blue Star17 Aug 2026 · ~1 year · target ₹1,800 · Active
- BUY State Bank of India17 Aug 2026 · ~1 year · target ₹1,265 · Active
- BUY Steel Authority of India1 Aug 2026 · ~1 year · target ₹220 · Active
- BUY Supreme Industries1 Aug 2026 · ~1 year · target ₹4,200 · Active
- BUY Tata Power Company1 Aug 2026 · ~1 year · target ₹450 · Active

